ENDPOINTS

Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

CHICAGO — Self-described “blunt pharma executives,” Jake Van Naarden and David Hyman of Eli Lilly sat down Sunday with Endpoints News at the annual ASCO conference. The biggest takeaway from a conversation with the Indianapolis ...

Jun 2, 2025 - 13:04
 0
Phase 3 or bust: Why Lilly won't run mid-stage cancer trials
CHICAGO — Self-described “blunt pharma executives,” Jake Van Naarden and David Hyman of Eli Lilly sat down Sunday with Endpoints News at the annual ASCO conference. The biggest takeaway from a conversation with the Indianapolis ...
Read More

Tags:

Previous Article

Korean startup Curogen seeks US expansion, funding to back autoimmune drugs

Next Article

#ASCO25: Enhertu combo has the makings of a new standard in HER2-positive breast...

Related Posts

CellCentric raises $120M to treat multiple myeloma with capsule

CellCentric raises $120M to treat multiple myeloma with...

May 19, 2025  0

UnitedHealth Group CEO Andrew Witty steps down

UnitedHealth Group CEO Andrew Witty steps down

May 13, 2025  0

FDA clears in vivo blood stem cell editing trial; Abeona's $155M PRV sale

FDA clears in vivo blood stem cell editing trial; Abeon...

May 12, 2025  0